UPDATE 1-Takeda Pharma reports five-fold increase in full-year profit Reuters 1 day ago
Popular Searches
TOKYO, May 11 (Reuters) - Takeda Pharmaceutical Co on Tuesday reported a five-fold increase in full-year operating profit versus the previous year, driven by sales of its Entyvio colitis treatment and other mainstay drugs.
Operating profit for Japan s largest drugmaker in the year to end March came in at 509 billion yen ($4.68 billion).
That compares with its own earlier estimate of 434 billion yen and a consensus estimate of 567 billion yen from a Refinitiv poll of 14 analysts.
Takeda is importing Moderna Inc s COVID-19 vaccine into Japan and on Monday said that interim results of clinical trials have been positive.
By Syndicated Content
May 11, 2021 | 4:46 AM
TOKYO (Reuters) – Takeda Pharmaceutical Co on Tuesday said it may double imports of Moderna Inc’s COVID-19 vaccine to help Japan speed up COVID-19 inoculation efforts that have trailed most wealthy countries.
Japan’s biggest drugmaker is handling the imports, and discussions are underway with the government to double shipments to 100 million, Takeda CEO Christophe Weber said.
“Japan is behind. So our goal now is to really support an acceleration of the vaccination,” Weber said in a conference call after the company released full-year earnings results.
The company had reported positive interim results from a domestic trial of the Moderna shot, and Weber said he expected approval to come “very soon”.